Table I.

Descriptive data shown for the total study group (SG) and subcategorized for patients with cognitive symptoms (CS) and presumed cognitively healthy patients with other medical problems (CH) as primary reason for admission.

Variable	Cognitive symptoms (CS, n = 52)	Cognitively healthy study group (CH, n = 29)	Total (SG, n = 81)	p-value (CS vs. CH)
Men, n (%)	26 (50)	7 (24)	33 (41)	0.023
Woman, n (%)	26 (50)	22 (76)	48 (59)	0.023
Native language, n (%)
Swedish	48 (92)	29 (100)	77 (95)	0.126
Non-Swedish	4 (8)	0 (0)	4 (5)	0.126
Age, (year)	78.2+5.6	75.2+5.5	77.2+5.7	0.024
Range	66–88	65–88	65–88
Education, (year)	9.9+3.7	11.2+3.9	10.4+3.8	0.135
Range	6–16	5–16	5–16
Duration of cognitive symptoms (years)	2.4+1.9	0 (0)	1.5+1.9	0.001
Range	1–9	0–0	0–9
Medical history, n (%)
Hypertension	33 (63)	16 (55)	49 (60)	0.464
Diabetic disease	7 (13)	1 (3)	8 (10)	0.148
Ischaemic heart disease	15 (29)	6 (21)	21 (26)	0.422
Cerebrovascular disease	6 (12)	0 (0)	6 (7)	0.057
Anxiety	4 (7)	0	4 (5)	0.126
Mild depression	6 (12)	1 (3)	7 (9)	0.214
Medical drugs, n (%)
Anxiolytic	12 (23)	4 (14)	16 (20)	0.314
Antidepressants	21 (40)	5 (17)	26 (32)	0.032
Sleeping drugs	17 (33)	5 (17)	22 (27)	0.134
Antipsychotics	4 (8)	0 (0)	4 (5)	0.126
Antihypertensive	40 (77)	18 (62)	58 (72)	0.155
Lipid lowering drugs	25 (48)	11 (38)	36 (44)	0.378
Salicylic acid (low-dose)	26 (50)	10 (34)	36 (44)	0.178
Warfarin	7 (13)	4 (14)	11 (14)	0.967
Insulin	4 (8)	0 (0)	4 (5)	0.126
Anti-diabetic	3 (6)	1 (3)	4 (5)	0.644

Data are shown as mean +/– 1 standard deviation (SD) and range (min–max). P-value analysed by chi-square for gender, medical history, and medical drugs, independent t-test used for age, education, and duration of cognitive symptoms (CS). Significant p-value < 0.05.